The pan-TRK-positive samples of three laboratories (CHU Liège, OLV, UZA) were subjected to targeted RNAseq with the
Oncomine Focus Assay (Thermo Fisher Scientific, San Francisco, CA, USA) on an S5 instrument, according to the manufacturer's instructions [30] . One laboratory (UZG) used the Archer Fusion-Plex Expanded Sarcoma Assay (ArcherDx, Boulder, CO, USA) for targeted RNAseq on the Illumina
MiSeq platform, with subsequent data analysis using the Archer Analysis Software. Three laboratories (Institut Jules Bordet, CUSL, UZL) used the Archer Fu-sionPlex comprehensive thyroid and lung panel (ArcherDX) for targeted RNAseq to investigate the presence of NTRK fusions, as was previously described [31] . One laboratory (AZ Delta) used an in-house developed gene panel for the identification of somatic mutations in 56 target genes, in combination with amplicon-based RNAseq (Illumina
Focus panel). Two laboratories (IPG, UZL) performed FISH analysis on 3-4-µm-thick FFPE tissue slides of pan-TRK-positive tumor samples. Details on these procedures can be found in the online supplementary Materials and Methods.
Van Bockstal M.R., Beniuga G., Craciun L., Creytens D., Dedeurwaerdere F., Delvenne P., Demetter P., De Wiest B., Dewinne K., Habran L., Pauwels P., Theate I., Vander Borght S., Van Der Steen K, & Weynand B. (2022). The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study. Pathobiology : journal of immunopathology, molecular and cellular biology, 89(6).